Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions

Executive Summary

Report sponsored by Association for Accessible Medicines in US says drugs with restricted distribution programs had total sales of $22.7bn in 2016; seven drugs had sales topping $1bn.

You may also be interested in...



Unapproved Uses Bill May Eventually Pass, But Would Likely Need Additional Safeguards

Off-label communication amendments tabled at House markup of user fee legislation after Democrats object; the two sides agreed to discuss the issue further down the road.

Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting

Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.

REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill

Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel